- Home
- CEE vs IMAB Comparison
CEE vs IMAB Comparison
Compare CEE & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CEE
- IMAB
- Stock Information
- Founded
- CEE 1990
- IMAB 2014
- Country
- CEE Germany
- IMAB United States
- Employees
- CEE N/A
- IMAB N/A
- Industry
- CEE Finance Companies
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- CEE Finance
- IMAB Health Care
- Exchange
- CEE Nasdaq
- IMAB Nasdaq
- Market Cap
- CEE 72.9M
- IMAB 87.2M
- IPO Year
- CEE N/A
- IMAB 2020
- Fundamental
- Price
- CEE $12.50
- IMAB $1.09
- Analyst Decision
- CEE
- IMAB Strong Buy
- Analyst Count
- CEE 0
- IMAB 3
- Target Price
- CEE N/A
- IMAB $8.00
- AVG Volume (30 Days)
- CEE 22.0K
- IMAB 672.9K
- Earning Date
- CEE 01-01-0001
- IMAB 03-13-2025
- Dividend Yield
- CEE 3.86%
- IMAB N/A
- EPS Growth
- CEE N/A
- IMAB N/A
- EPS
- CEE N/A
- IMAB N/A
- Revenue
- CEE N/A
- IMAB $3,313,984.00
- Revenue This Year
- CEE N/A
- IMAB N/A
- Revenue Next Year
- CEE N/A
- IMAB N/A
- P/E Ratio
- CEE N/A
- IMAB N/A
- Revenue Growth
- CEE N/A
- IMAB N/A
- 52 Week Low
- CEE $7.80
- IMAB $0.84
- 52 Week High
- CEE $10.32
- IMAB $2.08
- Technical
- Relative Strength Index (RSI)
- CEE 62.53
- IMAB 57.56
- Support Level
- CEE $11.65
- IMAB $1.00
- Resistance Level
- CEE $12.32
- IMAB $1.20
- Average True Range (ATR)
- CEE 0.36
- IMAB 0.11
- MACD
- CEE 0.11
- IMAB 0.02
- Stochastic Oscillator
- CEE 92.97
- IMAB 46.33
About CEE The Central and Eastern Europe Fund Inc. (The)
CENTRAL & EASTERN EUROPE FUND, INC. is a closed-end management investment company. The Fund's objective is to seek long-term capital appreciation. It invests in the equity or equity-linked securities of issuers domiciled in Central and Eastern Europe.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).